Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$KIN THIS DREW ME HERE PARTNERSHIP WIT VXRT !!!!![pill form]
$KIN THIS DREW ME HERE PARTNERSHIP WIT VXRT !!!!![pill form]
$KIN I LIKE YOUR BREAKOUT ANYTIME[SAUCER FORMATION]
$KIN Relieve Pyrexia[only drug FDA-approved for control of pyrexia in horses1]
at the source with Zimeta
The first and only drug FDA-approved for control of pyrexia in horses1
$KIN 7-29-2020 btm call;[da pill]Nasdaq:VXRT for the manufacture of oral vaccine candidate for COVID-19.
==============================================================
[Relieve Pyrexia at the source with Zimeta
The first and only drug FDA-approved for control of pyrexia in horses1]
==============================================================
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics,
today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said KindredBio’s Chief Executive Officer,
Richard Chin, M.D.
“This marks an important step in the development of our contract manufacturing business, which has the potential to help fund our promising pipeline.”
Under the terms of the agreement, KindredBio will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA.
There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices,
and provide it to Vaxart to be
formulated into a vaccine tablet to be taken by mouth
instead of by needle injection.
KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.
“We are pleased to be partnering with Kindred Biosciences in the development of our oral COVID-19 vaccine candidate,” said Vaxart’s Chief Executive Officer,
Wouter Latour, M.D.
“We believe our novel approach utilizing a room temperature-stable tablet offers important logistical advantages in widespread oral vaccination,
and that KindredBio with its state-of-the-art manufacturing plants is
an ideal partner to realize our vision.”
KindredBio’s core expertise includes protein engineering,
cell line development,
master cell banking, process development, assay development, stability testing, and
cGMP clinical and
commercial manufacturing from 50 litres to 2,000 litres.
The biologics team comprises experts in product development, manufacturing,
quality control and quality assurance personnel,
and is supported by a strong project management organization.
KindredBio’s contract development and manufacturing (CDMO) activities are managed by a wholly owned subsidiary,
Centaur Biopharmaceutical Services.
About Kindred Biosciences
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets.
Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.
The company’s strategy is to identify targets that have already demonstrated safety and efficacy in
humans and to develop therapeutics based on these validated targets for dogs and cats.
KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes,
alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
For more information, please visit: Http://www.kindredbio.com
About Vaxart
Vaxart is a clinical-stage biotechnology company and its oral recombinant vaccine candidate is based on its proprietary VAAST™ platform. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection.
For more information, please visit http://www.vaxart.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials,
regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.
These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products or to develop a satisfactory sales organization for our equine small molecule products; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers’ information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the risk that our 2020 strategic realignment plan will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that we will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.
For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.
The results stated in this press release have not been reviewed by the Food and Drug Administration or the United States Department of Agriculture Center for Veterinary Biologics, as applicable.
Contacts
For investor inquiries:
Katja Buhrer
Katja.buhrer@kindredbio.com
(917) 969-3438
For CDMO services:
Jeremy Vrchota
jeremy.vrchota@kindredbio.com
(605) 370-2258
Share this entry
$KIN 7-29-2020 btm call;Nasdaq:VXRT for the manufacture of oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics,
today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said KindredBio’s Chief Executive Officer,
Richard Chin, M.D.
“This marks an important step in the development of our contract manufacturing business, which has the potential to help fund our promising pipeline.”
Under the terms of the agreement, KindredBio will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA.
There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices,
and provide it to Vaxart to be
formulated into a vaccine tablet to be taken by mouth
instead of by needle injection.
KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.
“We are pleased to be partnering with Kindred Biosciences in the development of our oral COVID-19 vaccine candidate,” said Vaxart’s Chief Executive Officer,
Wouter Latour, M.D.
“We believe our novel approach utilizing a room temperature-stable tablet offers important logistical advantages in widespread oral vaccination,
and that KindredBio with its state-of-the-art manufacturing plants is
an ideal partner to realize our vision.”
KindredBio’s core expertise includes protein engineering,
cell line development,
master cell banking, process development, assay development, stability testing, and
cGMP clinical and
commercial manufacturing from 50 litres to 2,000 litres.
The biologics team comprises experts in product development, manufacturing,
quality control and quality assurance personnel,
and is supported by a strong project management organization.
KindredBio’s contract development and manufacturing (CDMO) activities are managed by a wholly owned subsidiary,
Centaur Biopharmaceutical Services.
About Kindred Biosciences
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets.
Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.
The company’s strategy is to identify targets that have already demonstrated safety and efficacy in
humans and to develop therapeutics based on these validated targets for dogs and cats.
KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes,
alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
For more information, please visit: Http://www.kindredbio.com
About Vaxart
Vaxart is a clinical-stage biotechnology company and its oral recombinant vaccine candidate is based on its proprietary VAAST™ platform. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection.
For more information, please visit http://www.vaxart.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials,
regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.
These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products or to develop a satisfactory sales organization for our equine small molecule products; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers’ information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the risk that our 2020 strategic realignment plan will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that we will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.
For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.
The results stated in this press release have not been reviewed by the Food and Drug Administration or the United States Department of Agriculture Center for Veterinary Biologics, as applicable.
Contacts
For investor inquiries:
Katja Buhrer
Katja.buhrer@kindredbio.com
(917) 969-3438
For CDMO services:
Jeremy Vrchota
jeremy.vrchota@kindredbio.com
(605) 370-2258
Share this entry
$KIN Kindred Biosciences, Inc.'s (KIN) CEO Richard Chin on Q2 2020 Results - Earnings Call Transcript
Aug. 8, 2020 1:10 PM ET | About: Kindred Biosciences, Inc. (KIN)
Q2: 08-05-20 Earnings Summary
Press Release
EPS of $0.65694 beats by $0.50 Revenue of $39.57M (3,101.21% Y/Y) beats by $27.52M
Subscribers Only
Earning Call Audio
Kindred Biosciences, Inc. (NASDAQ:KIN) Q2 2020 Results Earnings Conference Call August 5, 2020 4:30 PM ET
Company Participants
Richard Chin - Chief Executive Officer
Wendy Wee - Chief Financial Officer
Katja Buhrer - Vice President, Corporate Development and IR
Conference Call Participants
Jon Block - Stifel
Balaji Prasad - Barclays
Brandon Folkes - Cantor Fitzgerald
David Westenberg - Guggenheim Securities
Ben Haynor - Alliance Global Partners
RK - H.C. Wainwright
Nathan Weinstein - Aegis Capital
Operator
Welcome to the Second Quarter 2020 Financial Results Conference Call and Webcast for Kindred Biosciences. At this time, all participants have been placed on a listen-only mode. At the end of the prepared statements, participants will have the opportunity to ask questions.
Please note that the remarks today will include forward-looking statements and that actual results could differ materially from those projected or implied in our forward-looking statements. For a description of important factors that could cause actual results to differ, we refer you to the forward-looking statements in today’s press release and the note on forward-looking statements in the company’s SEC filings.
It is now my pleasure to turn the call over to KindredBio CEO, Richard Chin. Dr. Chin. You may please proceed.
Richard Chin
Thank you, Operator. Good afternoon. And welcome to our second quarter 2020 financial results call. Joining me today from the management team of KindredBio are Wendy Wee, our CFO; and Katja Buhrer, our VP of Corporate Development and Investor Relations.
Before I start, I would like to thank our Co-Founder, Denise for her incredible contributions to KindredBio. Denise has been instrumental in growing KindredBio into one of the world’s leading veterinary biopharmaceutical companies and I look forward to our ongoing collaboration on the Board, as we continue to realize our vision for this pioneering company we have built together.
Thanks to our recent strategic decisions, we are strongly positioned for success. Our focus is on our highest value programs and with the OpEx expected to drop to $10 million per quarter by Q4, we have the crash runway to see us through important milestones and thereby realize the value of our late-stage assets.
Turning to our pipeline. We are pleased with our progress in the second quarter. Manufacturing for our IL-31 antibody, which now has the user name, tirnovetmab has been going well and we continue to expect the pivotal study to start this year. Manufacturing scale up is tracking to our expectations.
As you know, atopic dermatitis is a very large attractive area. There are couple of approved products that in aggregate sell more than $800 million per year and they are still growing. To put this in perspective, $800 million is a size of a well selling human product, but instead of $1 billion to develop a drug, we can do so for $1,100 of that cost.
Now the currently marketed products are excellent drugs, but we think they are vulnerable to competition. Our market research clearly demonstrates that veterinarians are looking for additional options.
The current products obviously don’t work for every patient. Tirnovetmab with a high-affinity second-generation product and it has the potential to be very successful. We believe that the anti- IL-4R antibody could also be a blockbuster, given its advantage in terms of direct effect on the disease pathophysiology.
Earlier in the pipeline, we have other product candidates that we believe will be very attractive as well and those products also have potential to capture a significant share of this multi-billion dollar market. So far we believe, we are ahead of our competition in this field with the exception of the current incumbent and we are very excited about our highly promising dermatology pipeline.
KIN SIGNED AGREEMENT WIT $VXRT TO MAKE DA PILL.
Kindred Biosciences (KIN)
4.02 ? 0.04 (1.01%)
Volume: 144,673 @08/14/20 7:11:52 PM EDT
Bid Ask Day's Range
4.04 4.48 3.92 - 4.1
KIN Detailed Quote
$KIN wit $VXRT partnership this could be huge.[da pill]
$KIN [positive]Kindred Biosciences (KIN) Reports Next Week: Wall Street Expects Earnings Growth
11:33 am ET July 29, 2020 (Zacks) Print
The market expects Kindred Biosciences (KIN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2020. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on August 5, 2020, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This biopharmaceutical company is expected to post quarterly earnings of $0.15 per share in its upcoming report, which represents a year-over-year change of +140.5%.
Revenues are expected to be $19.82 million, up 1498.4% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
$KIN TARGET $11 Analyst's Opinion
Consensus Rating
Kindred Biosciences has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Kindred Biosciences has a potential upside of 228.4% from its current price of $3.35.
$KIN Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
HOW HAS KINDRED BIOSCIENCES' STOCK BEEN IMPACTED BY COVID-19 (CORONAVIRUS)?
https://www.marketbeat.com/stocks/NASDAQ/KIN/?RegistrationCode=SocialMedia-StockTwits&utm_source=GeneralSocialMedia&utm_medium=Social&utm_campaign=SocialMedia
Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KIN shares have decreased by 58.6% and is now trading at $3.35.
View which stocks have been most impacted by Coronavirus.
DO WALL STREET ANALYSTS RECOMMEND INVESTORS BUY SHARES OF KINDRED BIOSCIENCES?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kindred Biosciences.
WHEN IS KINDRED BIOSCIENCES' NEXT EARNINGS DATE?
Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Kindred Biosciences.
HOW CAN I LISTEN TO KINDRED BIOSCIENCES' EARNINGS CALL?
Kindred Biosciences will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
$KIN Centrally acting fever reduction
Causes of fever
Both internal (endogenous) or external (exogenous) substances can cause a febrile response in the horse. Most commonly, bacteria and viruses initiate a cascade of events leading to fever. However, neoplastic cells and host-derived antigen antibody complexes also can cause fever.1
Temperature is centrally regulated
After a febrile response is triggered, a complex cascade of events occurs centrally, leading to thermal conservation and an elevated hypothalamic set point. The main pathway to elevation of the hypothalamic set point is through arachidonic acid conversion to prostaglandin E2 (PGE2) catalyzed by cyclo-oxygenase (COX).2,3
Fever is a clinical sign mediated by cytokines, which are short polypeptide segments involved with cell signaling.3 Cytokines are also the mediators of the septic process. When unchecked, pyrogenic cytokines have the potential to be both harmful and beneficial during processes that result in the body generating fever.4
Dipyrone’s mechanism of action
Dipyrone, the active ingredient in Zimeta, is a member of the pyrazolone class of non-steroidal anti-inflammatory drugs (NSAIDs) and has a centrally acting mechanism of action on the hypothalamus, where fever originates and is regulated.*
There are multiple postulated mechanisms of actions of dipyrone as an antipyretic. As with all NSAIDs, dipyrone may inhibit fever via inhibition of COX. Additionally, dipyrone may also act as an antipyretic by decreasing arachidonic acid levels via the endocannabinoid pathway. There may also be two, non-prostaglandin-dependent mechanisms: via the endothelin pathway and via the direct endocannabinoid pathway.*
$KIN https://zimeta.com/about-fever-in-horses/
About Fever in Horses
Reasons why horses may experience elevated body temperature
In horses, elevated core body temperature (greater than 101.5°F) is the result of either hyperthermia or pyrexia (fever). Hyperthermia conditions include exercise-related hyperthermia, heat stroke, and reactions to certain toxins or drugs. In general, these conditions do not respond to antipyretic drugs.1
In a true fever, the set point for the physiologic core body temperature increases as a response to infection or inflammation. Although there are documented benefits of fever in many disease processes, managing fever also has benefits, particularly in the horse.1
Fever takes valuable energy
Nutrition is an important part of managing and treating sick horses. Fever increases caloric needs of horses, and inadequate nutrition may result in impaired immune system function, delayed wound or fracture healing, and/or muscle wasting.2
Fever can have serious secondary effects
Managing fever in a sick horse is important to help offset potential negative sequelae, including weakness, muscle wasting, and weight loss.1
Well-documented secondary effects of fever can include anorexia and decreased water intake, which may be associated with gastrointestinal impactions.1,3,4,5
Common causes of fever in horses
Fever is a clinical sign commonly associated with various underlying infectious and non-infectious diseases in the horse. Transportation of horses often results in fever, with incidence increasing with greater travel time and distances. One study showed fever occurred in 47.2% of clinically normal horses with no prior history of respiratory disease following transport.6
Diseases that may present with fever as a clinical sign include:
• Pneumonia/Pleuropneumonia7
• Acute diarrhea8
• Duodenitis/Proximal jejunitis8
• Internal infections10
These diseases are often associated with endotoxemia, a risk factor for sequelae including alminitis.11
$KIN Relieve Pyrexia at the source with Zimeta The first and only drug FDA-approved for control of pyrexia in horses1
[-chart]live-zimeta.pantheonsite.io/wp-content/uploads/2020/05/zimetalogo.png[/chart]
[-chart]zimeta.com/wp-content/uploads/2020/06/zimeta-product-shot-1.jpg[/chart]
https://zimeta.com/
$KIN MISCELLANEOUS Employees146 Outstanding Shares39,290,000
Market Cap$131.62 million
Next Earnings Date8/5/2020 (Confirmed)
OptionableOptionable
$KIN SALES & BOOK VALUE Book Value$2.10 per share Price / Book1.60
Annual Sales$4.26 million
Price / Sales30.90
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.10 per share
Price / Book1.60
$KIN 07-29-2020 btm.[wit $vxrt]Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics,
today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said KindredBio’s Chief Executive Officer,
Richard Chin, M.D.
“This marks an important step in the development of our contract manufacturing business, which has the potential to help fund our promising pipeline.”
Under the terms of the agreement, KindredBio will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA.
There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices,
and provide it to Vaxart to be
formulated into a vaccine tablet to be taken by mouth
instead of by needle injection.
KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.
“We are pleased to be partnering with Kindred Biosciences in the development of our oral COVID-19 vaccine candidate,” said Vaxart’s Chief Executive Officer,
Wouter Latour, M.D.
“We believe our novel approach utilizing a room temperature-stable tablet offers important logistical advantages in widespread oral vaccination,
and that KindredBio with its state-of-the-art manufacturing plants is
an ideal partner to realize our vision.”
KindredBio’s core expertise includes protein engineering,
cell line development,
master cell banking, process development, assay development, stability testing, and
cGMP clinical and
commercial manufacturing from 50 litres to 2,000 litres.
The biologics team comprises experts in product development, manufacturing,
quality control and quality assurance personnel,
and is supported by a strong project management organization.
KindredBio’s contract development and manufacturing (CDMO) activities are managed by a wholly owned subsidiary,
Centaur Biopharmaceutical Services.
About Kindred Biosciences
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets.
Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.
The company’s strategy is to identify targets that have already demonstrated safety and efficacy in
humans and to develop therapeutics based on these validated targets for dogs and cats.
KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes,
alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
For more information, please visit: Http://www.kindredbio.com
About Vaxart
Vaxart is a clinical-stage biotechnology company and its oral recombinant vaccine candidate is based on its proprietary VAAST™ platform. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection.
For more information, please visit http://www.vaxart.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.
These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products or to develop a satisfactory sales organization for our equine small molecule products; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers’ information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the risk that our 2020 strategic realignment plan will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that we will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.
For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.
The results stated in this press release have not been reviewed by the Food and Drug Administration or the United States Department of Agriculture Center for Veterinary Biologics, as applicable.
Contacts
For investor inquiries:
Katja Buhrer
Katja.buhrer@kindredbio.com
(917) 969-3438
For CDMO services:
Jeremy Vrchota
jeremy.vrchota@kindredbio.com
(605) 370-2258
Share this entry
$KIN BTM CALL TODAY MY FRIEND !!!!!
$KIN THIS DREW ME HERE PARTNERSHIP WIT VXRT !!!!![pill form]
$KIN Current Report Filing (8-k)
August 05 2020 - 04:10PM
Edgar (US Regulatory)
Alert
Print
Share On Facebook
$KIN outstanding Quarterly Report (10-q) Edgar (US
$KIN outstanding chart review.breakout saucer review, very bullish !!!!!
$KIN [da pill form] pay attention to dis partnering wit $VXRT manufacture of Vaxart’s oral vaccine candidate for COVID-19.
re;
$KIN 07-29-2020 btm.Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics,
today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said KindredBio’s Chief Executive Officer,
Richard Chin, M.D.
“This marks an important step in the development of our contract manufacturing business, which has the potential to help fund our promising pipeline.”
Under the terms of the agreement, KindredBio will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA.
There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices,
and provide it to Vaxart to be
formulated into a vaccine tablet to be taken by mouth
instead of by needle injection.
KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.
“We are pleased to be partnering with Kindred Biosciences in the development of our oral COVID-19 vaccine candidate,” said Vaxart’s Chief Executive Officer,
Wouter Latour, M.D.
“We believe our novel approach utilizing a room temperature-stable tablet offers important logistical advantages in widespread oral vaccination,
and that KindredBio with its state-of-the-art manufacturing plants is
an ideal partner to realize our vision.”
KindredBio’s core expertise includes protein engineering,
cell line development,
master cell banking, process development, assay development, stability testing, and
cGMP clinical and
commercial manufacturing from 50 litres to 2,000 litres.
$KIN Current Report Filing (8-k)
August 05 2020 - 04:10PM
Edgar (US Regulatory)
Alert
Print
Share On Facebook
$KIN outstanding Quarterly Report (10-q) Edgar (US
$KIN outstanding chart review.breakout saucer review, very bullish !!!!!
$KIN pay attention to dis partnering wit $VXRT manufacture of Vaxart’s oral vaccine candidate for COVID-19.
re;
$KIN 07-29-2020 btm.Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics,
today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said KindredBio’s Chief Executive Officer,
Richard Chin, M.D.
“This marks an important step in the development of our contract manufacturing business, which has the potential to help fund our promising pipeline.”
Under the terms of the agreement, KindredBio will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA.
There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices,
and provide it to Vaxart to be
formulated into a vaccine tablet to be taken by mouth
instead of by needle injection.
KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.
“We are pleased to be partnering with Kindred Biosciences in the development of our oral COVID-19 vaccine candidate,” said Vaxart’s Chief Executive Officer,
Wouter Latour, M.D.
“We believe our novel approach utilizing a room temperature-stable tablet offers important logistical advantages in widespread oral vaccination,
and that KindredBio with its state-of-the-art manufacturing plants is
an ideal partner to realize our vision.”
KindredBio’s core expertise includes protein engineering,
cell line development,
master cell banking, process development, assay development, stability testing, and
cGMP clinical and
commercial manufacturing from 50 litres to 2,000 litres.
$KIN Current Report Filing (8-k)
August 05 2020 - 04:10PM
Edgar (US Regulatory)
Alert
Print
Share On Facebook
$KIN outstanding Quarterly Report (10-q) Edgar (US
$KIN Kindred Biosciences Q2 EPS $0.60 Up From $(0.37) YoY, Sales $39.57M May Not Compare To $10.54M Estimate
4:26 pm ET August 5, 2020 (Benzinga) Print
Kindred Biosciences (NASDAQ:KIN) reported quarterly earnings of $0.60 per share. This is a 262.16 percent increase over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $39.57 million which beat the analyst consensus estimate of $10.54 million by 275.40 percent. This is a 3.10K percent increase over sales of $1.24 million the same period last year.
© 2020 http://www.Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
$KIN 3.3300 -0.0100 -0.2994% USD 1:32PM EDT 182.641k
$KIN07-29-2020 btm call;Nasdaq:VXRT for the manufacture of oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics,
today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said KindredBio’s Chief Executive Officer,
Richard Chin, M.D.
“This marks an important step in the development of our contract manufacturing business, which has the potential to help fund our promising pipeline.”
Under the terms of the agreement, KindredBio will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA.
There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices,
and provide it to Vaxart to be
formulated into a vaccine tablet to be taken by mouth
instead of by needle injection.
KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.
“We are pleased to be partnering with Kindred Biosciences in the development of our oral COVID-19 vaccine candidate,” said Vaxart’s Chief Executive Officer,
Wouter Latour, M.D.
“We believe our novel approach utilizing a room temperature-stable tablet offers important logistical advantages in widespread oral vaccination,
and that KindredBio with its state-of-the-art manufacturing plants is
an ideal partner to realize our vision.”
KindredBio’s core expertise includes protein engineering,
cell line development,
master cell banking, process development, assay development, stability testing, and
cGMP clinical and
commercial manufacturing from 50 litres to 2,000 litres.
The biologics team comprises experts in product development, manufacturing,
quality control and quality assurance personnel,
and is supported by a strong project management organization.
KindredBio’s contract development and manufacturing (CDMO) activities are managed by a wholly owned subsidiary,
Centaur Biopharmaceutical Services.
About Kindred Biosciences
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets.
Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.
The company’s strategy is to identify targets that have already demonstrated safety and efficacy in
humans and to develop therapeutics based on these validated targets for dogs and cats.
KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes,
alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
For more information, please visit: Http://www.kindredbio.com
About Vaxart
Vaxart is a clinical-stage biotechnology company and its oral recombinant vaccine candidate is based on its proprietary VAAST™ platform. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection.
For more information, please visit http://www.vaxart.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials,
regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.
These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products or to develop a satisfactory sales organization for our equine small molecule products; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers’ information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the risk that our 2020 strategic realignment plan will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that we will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.
For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.
The results stated in this press release have not been reviewed by the Food and Drug Administration or the United States Department of Agriculture Center for Veterinary Biologics, as applicable.
Contacts
For investor inquiries:
Katja Buhrer
Katja.buhrer@kindredbio.com
(917) 969-3438
For CDMO services:
Jeremy Vrchota
jeremy.vrchota@kindredbio.com
(605) 370-2258
Share this entry
$KIN wit $VXRT partnership this could be huge.
KIN watching, thanks mick
$KIN [positive]Kindred Biosciences (KIN) Reports Next Week: Wall Street Expects Earnings Growth
11:33 am ET July 29, 2020 (Zacks) Print
The market expects Kindred Biosciences (KIN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2020. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on August 5, 2020, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This biopharmaceutical company is expected to post quarterly earnings of $0.15 per share in its upcoming report, which represents a year-over-year change of +140.5%.
Revenues are expected to be $19.82 million, up 1498.4% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
$KIN TARGET $11 Analyst's Opinion
Consensus Rating
Kindred Biosciences has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Kindred Biosciences has a potential upside of 228.4% from its current price of $3.35.
$KIN Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
HOW HAS KINDRED BIOSCIENCES' STOCK BEEN IMPACTED BY COVID-19 (CORONAVIRUS)?
https://www.marketbeat.com/stocks/NASDAQ/KIN/?RegistrationCode=SocialMedia-StockTwits&utm_source=GeneralSocialMedia&utm_medium=Social&utm_campaign=SocialMedia
Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KIN shares have decreased by 58.6% and is now trading at $3.35.
View which stocks have been most impacted by Coronavirus.
DO WALL STREET ANALYSTS RECOMMEND INVESTORS BUY SHARES OF KINDRED BIOSCIENCES?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kindred Biosciences.
WHEN IS KINDRED BIOSCIENCES' NEXT EARNINGS DATE?
Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Kindred Biosciences.
HOW CAN I LISTEN TO KINDRED BIOSCIENCES' EARNINGS CALL?
Kindred Biosciences will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
$KIN Centrally acting fever reduction
Causes of fever
Both internal (endogenous) or external (exogenous) substances can cause a febrile response in the horse. Most commonly, bacteria and viruses initiate a cascade of events leading to fever. However, neoplastic cells and host-derived antigen antibody complexes also can cause fever.1
Temperature is centrally regulated
After a febrile response is triggered, a complex cascade of events occurs centrally, leading to thermal conservation and an elevated hypothalamic set point. The main pathway to elevation of the hypothalamic set point is through arachidonic acid conversion to prostaglandin E2 (PGE2) catalyzed by cyclo-oxygenase (COX).2,3
Fever is a clinical sign mediated by cytokines, which are short polypeptide segments involved with cell signaling.3 Cytokines are also the mediators of the septic process. When unchecked, pyrogenic cytokines have the potential to be both harmful and beneficial during processes that result in the body generating fever.4
Dipyrone’s mechanism of action
Dipyrone, the active ingredient in Zimeta, is a member of the pyrazolone class of non-steroidal anti-inflammatory drugs (NSAIDs) and has a centrally acting mechanism of action on the hypothalamus, where fever originates and is regulated.*
There are multiple postulated mechanisms of actions of dipyrone as an antipyretic. As with all NSAIDs, dipyrone may inhibit fever via inhibition of COX. Additionally, dipyrone may also act as an antipyretic by decreasing arachidonic acid levels via the endocannabinoid pathway. There may also be two, non-prostaglandin-dependent mechanisms: via the endothelin pathway and via the direct endocannabinoid pathway.*
$KIN https://zimeta.com/about-fever-in-horses/
About Fever in Horses
Reasons why horses may experience elevated body temperature
In horses, elevated core body temperature (greater than 101.5°F) is the result of either hyperthermia or pyrexia (fever). Hyperthermia conditions include exercise-related hyperthermia, heat stroke, and reactions to certain toxins or drugs. In general, these conditions do not respond to antipyretic drugs.1
In a true fever, the set point for the physiologic core body temperature increases as a response to infection or inflammation. Although there are documented benefits of fever in many disease processes, managing fever also has benefits, particularly in the horse.1
Fever takes valuable energy
Nutrition is an important part of managing and treating sick horses. Fever increases caloric needs of horses, and inadequate nutrition may result in impaired immune system function, delayed wound or fracture healing, and/or muscle wasting.2
Fever can have serious secondary effects
Managing fever in a sick horse is important to help offset potential negative sequelae, including weakness, muscle wasting, and weight loss.1
Well-documented secondary effects of fever can include anorexia and decreased water intake, which may be associated with gastrointestinal impactions.1,3,4,5
Common causes of fever in horses
Fever is a clinical sign commonly associated with various underlying infectious and non-infectious diseases in the horse. Transportation of horses often results in fever, with incidence increasing with greater travel time and distances. One study showed fever occurred in 47.2% of clinically normal horses with no prior history of respiratory disease following transport.6
Diseases that may present with fever as a clinical sign include:
• Pneumonia/Pleuropneumonia7
• Acute diarrhea8
• Duodenitis/Proximal jejunitis8
• Internal infections10
These diseases are often associated with endotoxemia, a risk factor for sequelae including alminitis.11
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
144
|
Created
|
01/04/14
|
Type
|
Free
|
Moderators |
Kindred Biosciences Announces Plan to Strengthen its Strategic Position
June 8, 2020
SAN FRANCISCO , June 8, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
SAN FRANCISCO , May 20, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
May 13, 2020
SAN FRANCISCO , May 13, 2020 /PRNewswire/ -- Kindred Biosciences , Inc. (NASDAQ: ...
Kindred Biosciences Announces First Quarter 2020 Financial Results
May 7, 2020
SAN FRANCISCO , May 7, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
Kindred Biosciences to Announce First Quarter 2020 Financial Results
April 23, 2020
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. P...
Kindred Biosciences Announces Completion of Mirataz® (mirtazapine transdermal ointment) Transaction
April 15, 2020
$KIN 07-29-2020 btm.Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics,
today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said KindredBio’s Chief Executive Officer,
Richard Chin, M.D.
“This marks an important step in the development of our contract manufacturing business, which has the potential to help fund our promising pipeline.”
Under the terms of the agreement, KindredBio will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA.
There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices,
and provide it to Vaxart to be
formulated into a vaccine tablet to be taken by mouth
instead of by needle injection.
KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.
“We are pleased to be partnering with Kindred Biosciences in the development of our oral COVID-19 vaccine candidate,” said Vaxart’s Chief Executive Officer,
Wouter Latour, M.D.
“We believe our novel approach utilizing a room temperature-stable tablet offers important logistical advantages in widespread oral vaccination,
and that KindredBio with its state-of-the-art manufacturing plants is
an ideal partner to realize our vision.”
KindredBio’s core expertise includes protein engineering,
cell line development,
master cell banking, process development, assay development, stability testing, and
cGMP clinical and
commercial manufacturing from 50 litres to 2,000 litres.
PER MGMT DAVE -
IH Geek [Dave] DISCLAIMER |
01-31-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |